Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 7Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Classical hematology 1CNS 1

Conditions

Multiple Myeloma 25Leukemia, Myeloid, Acute 22Precursor Cell Lymphoblastic Leukemia-Lymphoma 21Lymphoma 21Burkitt Lymphoma 19Myelodysplastic Syndromes 17Leukemia 17Lymphoma, Non-Hodgkin 15Lymphoma, Follicular 15Lymphoma, Large B-Cell, Diffuse 14Leukemia, Lymphocytic, Chronic, B-Cell 13Lymphoma, Mantle-Cell 12Lymphoma, B-Cell, Marginal Zone 12Neoplasms, Plasma Cell 11Lymphoma, Large-Cell, Immunoblastic 11Hodgkin Disease 11Breast Neoplasms 11Recurrence 10Congenital Abnormalities 9Sarcoma 8Dendritic Cell Sarcoma, Interdigitating 8Myeloproliferative Disorders 7Leukemia, Myelomonocytic, Juvenile 7Leukemia, Myeloid, Chronic-Phase 7Lymphoma, T-Cell, Cutaneous 6Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 6Leukemia, Myeloid, Accelerated Phase 6Leukemia, Hairy Cell 6Central Nervous System Neoplasms 6Sezary Syndrome 5

Interventions

Rituximab 5Peripheral Blood Stem Cell Transplantation 3Lenalidomide 2Ipilimumab 2Etoposide 2Dasatinib 2Cyclophosphamide 2CTLA-4 Antigen 2tanespimycin 1sodium thiosulfate 1pegfilgrastim 1obatoclax 1ibrutinib 1fludarabine phosphate 1etoposide phosphate 1devimistat 1belinostat 1amuvatinib 1Vorinostat 1Vincristine 1Tacrolimus 1Sirolimus 1Razoxane 1Radiotherapy, Intensity-Modulated 1Radiotherapy 1Radiation 1Oxycodone 1Oxaliplatin 1Moxifloxacin 1Morphine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Intraocular Lymphoma × Filgrastim × Clear all
NCT00074165 2023-07-06

Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen

OHSU Knight Cancer Institute

Phase 2 Terminated
17 enrolled 7 charts
CNSClassical hematologyLymphoid

Lymphoma, Thrombocytopenia, Central Nervous System Neoplasms, Intraocular Lymphoma, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡